一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-143 号 一心堂药业集团股份有限公司 关于公司股东阮鸿献先生部分股票质押融资 提前还款解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司（以下简称"公司"）近日接到公司股东阮鸿献先生通知， 获悉阮鸿献先生与中国中金财富证券有限公司（以下简称"中金财富"）达成协议，将 2024 年 6 月 6 日向中金财富申请办理的股票质押融资业务进行部分股票质押融资提前还款并解除股 票质押，具体事项如下： 一、股东股份质押情况 1、股份质押解除情况 截至本公告披露日,阮鸿献先生及其一致行动人所持股份累计被质押情况如下: | 股东名称 | 持股数量（万 | 持股比 | 本次解除 | 本次解除 | 合计占 | 合计占 | 已质押股份情 | 未质押股份情况 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 股） | 例 | 质押前质 | 质押后质 | 其所持 | 公司总 | 况 | （注 ...

Core Viewpoint - YXTT's stock price has shown volatility with a recent decline, while the company has experienced a decrease in revenue and net profit year-on-year [1][2]. Group 1: Stock Performance - On December 29, YXTT's stock fell by 2.06%, trading at 13.32 CNY per share with a total market capitalization of 7.8 billion CNY [1]. - Year-to-date, YXTT's stock price has increased by 6.30%, but it has decreased by 4.17% over the last five trading days [1]. - The company has appeared on the trading leaderboard twice this year, with the most recent instance on May 23, where it recorded a net buy of -4.0951 million CNY [1]. Group 2: Financial Performance - For the period from January to September 2025, YXTT reported a revenue of 13 billion CNY, a year-on-year decrease of 4.33%, and a net profit of 269 million CNY, down 8.17% year-on-year [2]. - Since its A-share listing, YXTT has distributed a total of 2.023 billion CNY in dividends, with 764 million CNY distributed over the last three years [3]. Group 3: Shareholder Information - As of September 30, 2025, YXTT had 37,500 shareholders, an increase of 10.53% from the previous period, with an average of 10,596 shares per shareholder, down 9.53% [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 3.74 million shares to 22.3144 million shares [3].

Summary of the Pharmacy Industry Conference Call Industry Overview - The pharmacy industry is undergoing significant changes due to tightened medical insurance policies and regular inspections, leading to the exit of non-compliant pharmacies and benefiting leading chain enterprises [1][2] - The overall pharmaceutical market is experiencing a decline, with retail sales showing a slight increase in online channels while offline sales are decreasing [1][4] Key Points and Arguments Regulatory Changes - From 2025, pharmacies must complete sales closure scanning, and by January 2026, all medical institutions must collect and upload drug traceability codes, enhancing industry compliance [1][4] - The National Medical Insurance Bureau has increased inspections, with approximately 42%-43% of pharmacies relying on medical insurance, leading to many pharmacies voluntarily exiting the insurance system [2] Financial Performance - The retail pharmacy gross margin has decreased from 33.4% to 28.6% due to centralized procurement policies, putting pressure on net profits for listed companies [1][4] - The overall pharmaceutical market sales declined by 1.1% year-on-year in the first three quarters, with hospital sales down 2.5% and retail sales up 3.2% [4] Market Dynamics - O2O (Online to Offline) channels are expected to grow by 36% in 2025, with sales projected to reach between 44 billion to 45 billion yuan, accounting for over 10% of total sales for leading chain enterprises [1][4] - The number of large chain brands has decreased, with over 15,000 stores closed in the first three quarters of 2025 [6] Additional Important Insights Strategic Adjustments - Leading chain pharmacies are slowing down expansion and focusing on profitability, optimizing store structures, and increasing franchise opportunities [3][6] - The industry is witnessing a shift towards diversified business models, including cross-industry collaborations and the establishment of DTP (Direct-to-Patient) pharmacies [3][19] Future Trends - The pharmacy industry is expected to continue its consolidation and cleaning process over the next two years, with a projected reduction of several thousand underperforming pharmacies annually [29] - By the end of 2026, the number of pharmacies is anticipated to stabilize around 500,000, marking a new phase of stable development and potential for large-scale mergers and acquisitions [29] Digital Transformation - Emphasis on digital capabilities and the integration of online and offline operations is crucial for enhancing operational efficiency and customer experience [8][25] - The industry is exploring innovative services such as telemedicine and smart delivery to improve customer engagement and service quality [8][19] Policy Support - Recent policies aim to simplify approval processes and encourage mergers, which could enhance competitiveness and drive industry consolidation [22][24] This summary encapsulates the key insights and developments within the pharmacy industry as discussed in the conference call, highlighting the regulatory environment, financial performance, market dynamics, strategic adjustments, future trends, digital transformation, and policy support.

Group 1 - The Yunnan Provincial Party Committee's 11th Plenary Session and Economic Work Conference have outlined a grand blueprint for the "14th Five-Year Plan," emphasizing the importance of enterprises in driving economic progress and contributing to the modernization of Yunnan [1][2] - Various enterprises in Yunnan, both state-owned and private, are actively engaging in learning and implementing the conference's directives, aiming to enhance their roles in economic development [1][2][8] - The focus is on creating a market-oriented, legal, and international business environment to stimulate high-quality development and support the growth of various enterprises [2][8] Group 2 - Yunnan Investment Management Company aims to enhance regional financial stability and service strategic collaboration, focusing on optimizing development paths and improving services for the real economy [2][3] - YunTianHua Group is committed to advancing green and high-quality development, balancing traditional industry upgrades with emerging industry innovations, and leveraging regional advantages for project development [3][4] - Yunnan Construction Investment Group has accumulated significant assets and is focusing on integrating transportation, logistics, energy, and tourism sectors to enhance project applications and drive economic corridors [5][6] Group 3 - Yunnan Coffee Factory is set to enhance its processing capabilities and brand presence, aiming to elevate the coffee industry in Yunnan through innovation and quality control [6][7] - The emphasis on supporting private enterprises is evident, with initiatives to promote project opportunities and reduce burdens on businesses, fostering a supportive environment for innovation and growth [8][10] - Yunnan's private enterprises are encouraged to focus on core responsibilities and enhance competitiveness, particularly in resource-based industries, to contribute to the province's economic transformation [9][10]

Group 1 - The Yunnan provincial government has outlined a grand blueprint for the "14th Five-Year Plan," emphasizing the importance of both state-owned and private enterprises in driving economic progress and contributing to the modernization of Yunnan [1][2] - The provincial meetings highlighted the need to enhance the business environment, stimulate the vitality of various business entities, and support the growth of enterprises to promote high-quality development [2][8] - Companies like Yunnan Investment Management Co. and Yunnan Tianhua Group are committed to focusing on their core responsibilities and enhancing their main businesses to align with the provincial economic development goals [2][3] Group 2 - Yunnan Copper Holdings aims to establish a comprehensive value support system for its industrial group by 2025, with significant increases in profit indicators and a focus on steady operations amid uncertainties [4] - Yunnan Construction Investment Group has successfully managed 160 investment projects, with total assets reaching 450 billion yuan by the end of the "14th Five-Year Plan," and plans to integrate various industries to enhance economic corridors [5] - Yunnan Coffee Factory is set to improve its processing capabilities and brand presence, aiming to elevate the "Yunfei" brand to a national level while supporting local farmers through various initiatives [6][7] Group 3 - The provincial meetings have fostered a strong consensus among enterprises to pursue high-quality development, with companies like Xiangfeng Group and Yunnan Dianxue Grain and Oil Co. expressing confidence in their growth strategies [9][10] - Yunnan Duobao Cable Group is focusing on the development of new energy cable products and energy-saving transformations, leveraging regional advantages to enhance infrastructure in Southeast Asia [10] - The overall sentiment among various enterprises is one of determination to translate provincial directives into actionable strategies for growth and innovation, contributing to the success of the "14th Five-Year Plan" [10]

证券日报网讯12月26日，一心堂（002727）在互动平台回答投资者提问时表示，公司密切关注并严格遵 循《互联网平台价格行为规则》等政策导向，始终坚持聚焦药品零售主业，核心战略在于持续提升专业 药事服务能力和顾客体验。对于线上渠道，公司以顾客需求为中心，不断优化"一心到家"与第三方平台 在内的多渠道服务矩阵，致力于为消费者提供更优服务，实现健康可持续发展。 ...

Investment Rating - The report suggests a positive outlook for the pharmacy and traditional Chinese medicine sectors, anticipating a recovery in 2026 after a weak performance in 2025 [2][5]. Core Insights - The pharmacy sector is expected to benefit from market consolidation, with leading companies likely to increase their market share through mergers and acquisitions during the industry clearing phase [3][11]. - The traditional Chinese medicine sector is projected to stabilize and potentially recover, driven by an increase in flu incidence and the upcoming update of the essential drug list [57][60]. Summary by Sections Pharmacy Sector - **Market Review**: The pharmacy sector faced significant challenges in 2025, with a decline in same-store sales and an overall reduction in the number of operating stores since Q4 2024 [5][20]. - **Policy Environment**: Regulatory measures are promoting a more compliant and healthier industry ecosystem, which is expected to benefit leading companies [14][15]. - **Market Size**: In the first ten months of 2025, the sales scale of physical pharmacies was 501.3 billion yuan, a year-on-year decrease of 1.6%, primarily due to a decline in non-pharmaceutical sales [16][21]. - **Competitive Landscape**: The number of pharmacies in China reached approximately 684,000 by the end of 2024, with a notable increase in store closures, particularly among smaller chains [20][24]. - **Marginal Performance**: There has been a slight recovery in retail sales data, with leading companies showing improved performance through cost reduction and efficiency measures [32][34]. - **Outlook for 2026**: Focus on market consolidation and the development of non-pharmaceutical products is recommended, as leading companies are expected to enhance their market share [44][52]. Traditional Chinese Medicine Sector - **Market Review**: The traditional Chinese medicine sector experienced overall weak performance in 2025, with some companies seeing temporary valuation increases due to innovative pipelines [57][58]. - **In-Hospital Opportunities**: The upcoming update of the essential drug list is expected to benefit companies with products that have the potential to be included [60]. - **Out-of-Hospital Opportunities**: An increase in flu incidence in Q4 2025 is anticipated to aid in inventory digestion, with some companies expected to see improved performance [60]. - **High Dividend Stocks**: Companies such as Lingrui Pharmaceutical, Jichuan Pharmaceutical, and Dong'e Ejiao are highlighted as stable high-dividend investment opportunities [60].

Group 1: Industry Environment - The international college market has become a battleground for fashion and beauty brands, with Generation Z's annual beauty spending reaching $5 billion, and skincare usage starting as early as ages 11-13, showing a trend of gender convergence in consumption [3] - Brands are leveraging campus ambassadors, pop-up events, social media, and influencer collaborations to penetrate the college market, while health brands utilize clubs and TikTok to reach their target audience [3] - The strong purchasing power and loyalty of Generation Z make campus settings strategic for brands, necessitating innovative activities to capture attention [3] Group 2: Market Dynamics - Traditional chain pharmacies are accelerating their transformation by expanding into beauty and personal care categories to address industry challenges, with YST planning to add beauty and maternal products in 70% of its stores (nearly 8,000 locations) [5] - The beauty segment now accounts for nearly 60% of the health category in these pharmacies, as other chains like Shuyupingmin and Yifeng also enter the beauty market to cope with tightening medical insurance policies and declining foot traffic [5] - Cosmetic brands such as Winona and Kefu Mei are actively entering pharmacy channels to enhance brand value through professional credibility, although expanding OTC channels requires significant investment and faces challenges in product selection and private domain operations [5] Group 3: Major Brand Developments - Major beauty brands like L'Oréal and Estée Lauder have signed global ambassadors, enhancing their brand influence, while LVMH invests in the French niche fragrance brand BDK to support its international expansion [6] - The clean beauty sector is experiencing differentiation, with Korean brand Aromatica's stock surging while L'Oréal shuts down related brands [6] - Japanese high-end brand SUQQU is entering the Chinese market, targeting the premium segment [6] Group 4: Technological Innovations - Estée Lauder Group has launched a global innovation center for fragrance in Paris, integrating R&D and creative teams, utilizing AI to monitor trends, optimize formulas, and accelerate approval processes while respecting brand uniqueness [7] - AI assists perfumers in innovation by analyzing data and emotional preferences, with the launch of an AI fragrance consultant tool by Jo Malone in December, providing personalized fragrance recommendations [7] Group 5: Company Performance - Huaxi Biological has faced declining performance due to the diminishing market dividends of hyaluronic acid, with a 18.36% year-on-year revenue drop and a 30.29% decline in net profit for the first three quarters of 2024, resulting in a market value loss of 100 billion [8] - The company has adjusted welfare policies, reduced employee benefits, and cut staff, particularly in sales, while its skincare business has seen significant revenue declines and multiple sub-brands have been eliminated [8] - Increased competition and product homogenization in the hyaluronic acid market have pressured profits, prompting Huaxi Biological to explore new sectors like weight loss and invest in small nucleic acid drugs, although it faces fierce industry competition and consumer skepticism regarding ingredients [8] Group 6: Digital Transformation - Digitalization is increasingly important in retail for product management, marketing, and user experience, especially in a saturated market, necessitating innovative digital transformations to enhance efficiency [9] - Huamei's collaboration with Hanshu Technology has been recognized as an excellent digital innovation case, reshaping the beauty store shopping experience through a "warehouse-style display + artistic aesthetics" model [9] - The use of electronic price tags supports real-time information updates and enhances marketing conversion, demonstrating how digitalization can seamlessly integrate into brand identity and improve customer experience [9]

Core Insights - The domestic chain pharmacy industry is entering a period of negative growth, with the total number of pharmacies in China expected to drop below 700,000 by Q1 2025, marking a significant decline in the number of stores [1][2] - The market is undergoing a profound restructuring, with the total market size for pharmaceuticals reaching 2.03 trillion yuan in 2024, but with a mere 0.9% year-on-year growth, and a forecasted decline to 1.97 trillion yuan in 2025 [1][2] - Major chain pharmacies are experiencing divergent performance, with companies like Dazhonglin and Yifeng Pharmacy reporting profit increases, while Yixin Tang faces profit declines [1][3] Industry Trends - Predictions indicate that the number of pharmacy closures in 2025 could reach between 50,000 and 100,000, as the industry shifts from rapid expansion to a focus on value enhancement [2][3] - The industry is moving towards a "sell health" model, transitioning from traditional pharmaceutical sales to a more comprehensive health service approach [2][6] Market Dynamics - The closure of stores is expected to continue into 2025, with the industry potentially returning to a more sustainable scale of around 500,000 pharmacies, similar to 2018 levels [3] - The overall non-pharmaceutical sales proportion in the industry has reached 34.6% in 2025, up 5.2 percentage points from 2024, indicating a shift towards health-related products and services [4][6] Competitive Landscape - The market concentration is increasing, with the top ten chain pharmacy brands holding a combined market share of 58% in Q3 2025, up 5 percentage points from 2024 [4] - Franchise models are becoming a key strategy for leading chain pharmacies to expand market share, with significant increases in franchise store openings reported [5][6] Transformation Strategies - The core development direction for chain pharmacies in 2025 is professional transformation, with a focus on innovative drugs and DTP pharmacy models [6][9] - The shift towards chronic disease management and health service offerings is becoming increasingly important, with pharmacies enhancing their service capabilities to meet patient needs [7][9] Future Outlook - Despite current challenges, industry experts believe that the long-term trend for the chain pharmacy sector remains positive, driven by supply-side adjustments and demand recovery [8][9] - The future of chain pharmacies is expected to revolve around becoming health service providers, integrating pharmaceutical resources with community health needs [9]

Core Viewpoint - The domestic chain pharmacy industry is entering a period of negative growth, with a significant reduction in the number of pharmacies and a shift from rapid expansion to a focus on value enhancement and health services [2][3][11] Industry Overview - By Q1 2025, the total number of pharmacies in China is expected to fall below 700,000, with a net decrease of approximately 3,000 stores in a single quarter, indicating a widespread "store closure wave" [2] - The overall market size for pharmaceuticals is projected to reach 2.03 trillion yuan in 2024, but the growth rate is only 0.9%, with a forecasted decline to 1.97 trillion yuan in 2025 [2] Company Performance - Major chain pharmacies are experiencing divergent performance: Dazhenglin reported a net profit of 1.081 billion yuan in the first three quarters of 2025, up 25.97% year-on-year; Yifeng Pharmacy's net profit reached 1.225 billion yuan, a 10.27% increase; while Yixintang faced a decline with a net profit of 269 million yuan, down 8.17% [2] Store Closure Trends - Predictions indicate that the number of pharmacy closures in 2025 could reach between 50,000 and 100,000, marking a shift from the previous era of aggressive expansion to a focus on operational efficiency [3][4] - The industry is expected to return to a more reasonable scale of around 500,000 pharmacies, similar to levels seen in 2018 [4] Market Dynamics - The closure wave is driven by oversupply and increased regulatory pressures, with a significant rise in the proportion of non-pharmaceutical sales, which reached 34.6% in 2025, up 5.2 percentage points from 2024 [5] - The market share of the top ten pharmacy brands increased to 58% in Q3 2025, reflecting a growing concentration in the industry as smaller players exit [5] Business Model Evolution - The franchise model is becoming a key strategy for leading pharmacy chains to expand market share, with significant increases in franchise store openings reported [6] - The industry is transitioning from a focus on selling drugs to providing health services, with a notable shift towards a "sell health" approach [6][7] Professionalization and Service Enhancement - Professionalization is identified as a core development direction, with leading companies adopting innovative drug and DTP pharmacy models to enhance service delivery [7] - Community pharmacies are increasingly focusing on chronic disease management, with a significant percentage of patients expressing a desire for medication guidance and health management services [8] Diversification and Digital Transformation - Leading pharmacies are diversifying their offerings to include health-related products and services, transforming into comprehensive health experience hubs [9] - The integration of online and offline channels is accelerating, with significant growth in new retail segments and contributions from O2O channels [9] Future Outlook - Despite current challenges, industry experts believe that the long-term trend for the chain pharmacy sector remains positive, driven by supply-side adjustments and demand recovery [10] - The future of pharmacies is expected to focus on building a diversified health service ecosystem, aligning with national health strategies and enhancing both social and economic benefits [10][11]